Understanding Kisqali Hair Loss: What You Need to Know

For individuals diagnosed with metastatic breast cancer, finding effective treatment options can be a daunting task. Kisqali, also known as ribociclib, has emerged as a promising targeted therapy for hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer. As patients undergo treatment, they may experience hair loss as a side effect.

In this article, we will delve into the world of Kisqali hair loss, exploring its causes, management strategies, and what you can expect during your journey with this medication.

Initial Success and Hair Loss

When starting treatment with Kisqali, patients often experience initial success. Inspire member Sarah shared her story, stating that after taking 18 cycles of Kisqali, her CEA elevated to 93, indicating a positive response to the medication. However, she also experienced hair loss as a side effect.

Understanding Hair Loss

Hair loss is a common side effect associated with Kisqali treatment, particularly when combined with other medications like Femara. According to Inspire member Emily, who has been diagnosed with metastatic breast cancer, her oncologist prescribed Kisqali and Femara, which proved highly effective in reducing her tumor markers.

Types of Breast Cancer Treated

Ribociclib is primarily used to treat HR+ and HER2- breast cancer. The medication can be prescribed for off-label uses, and its efficacy has been demonstrated in various clinical trials. Types of breast cancer that may be treated with ribociclib include:

* Breast cancer in women who have not been treated with hormone therapy

* Breast cancer in postmenopausal women who have not been treated with hormone therapy or whose disease progressed while receiving hormone therapy

Targeted Therapy and Hair Loss

Kisqali is a targeted therapy that inhibits the growth and division of two cyclin-dependent kinases called CDK4 and CDK6. This mechanism helps slow or stop cancer growth, making it an effective treatment option for patients with metastatic breast cancer.

While hair loss may be a temporary side effect, it's essential to note that Kisqali is not designed to cause permanent hair loss. In many cases, hair regrowth occurs once the medication is discontinued or adjusted.

Managing Hair Loss

To cope with hair loss during Kisqali treatment, patients can try the following strategies:

* Use gentle hair care products and avoid heat styling tools

* Wear wigs, hats, or scarves to conceal thinning hair

* Consider consulting a dermatologist for further guidance on managing hair loss

Inspiring Stories of Success

Inspire member Sarah shared her remarkable story, stating that after taking 18 cycles of Kisqali, her CEA elevated to 93. Another Inspire member, Emily, has been diagnosed with metastatic breast cancer and is currently undergoing treatment with Kisqali and Femara. Her PET/CT scan results have shown significant regression in bone mets, and she is hopeful about her future.

Kisqali hair loss is a common side effect associated with this targeted therapy. While it may be unsettling to experience hair loss during treatment, understanding its causes and management strategies can help alleviate concerns. By sharing inspiring stories of success and exploring ways to manage hair loss, patients can navigate their journey with Kisqali treatment with confidence.

1. Inspire member Sarah's story

2. Inspire member Emily's story

3. National Cancer Institute (NCI)

4. American Society of Clinical Oncology (ASCO)